Last reviewed · How we verify

RSV-F Vaccine — Competitive Intelligence Brief

RSV-F Vaccine (RSV-F Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant protein vaccine RSV fusion (F) protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

RSV-F Vaccine (RSV-F Vaccine) — Novavax. RSV-F Vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus fusion (F) protein, preventing RSV infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RSV-F Vaccine TARGET RSV-F Vaccine Novavax phase 3 Recombinant protein vaccine RSV fusion (F) protein
Recombinant influenza hemagglutinin Recombinant influenza hemagglutinin Vaxine Pty Ltd marketed Recombinant protein vaccine Influenza hemagglutinin
Meningococcal B (Bexsero) Meningococcal B (Bexsero) University of Sao Paulo General Hospital marketed Recombinant protein vaccine Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)
Licensed seasonal influenza vaccine Licensed seasonal influenza vaccine Novavax marketed Recombinant protein vaccine with adjuvant Influenza hemagglutinin (HA) protein
Novavax recombinant protein vaccine Novavax recombinant protein vaccine Henry M. Jackson Foundation for the Advancement of Military Medicine marketed Recombinant protein vaccine Viral surface antigens (e.g., SARS-CoV-2 spike protein)
FluBlok FluBlok The University of Hong Kong marketed Recombinant protein vaccine Influenza hemagglutinin (HA)
Licensed 4CMenB vaccine Licensed 4CMenB vaccine University of Adelaide marketed Recombinant protein vaccine Neisseria meningitidis serogroup B surface antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

  1. GlaxoSmithKline · 6 drugs in this class
  2. Novavax · 5 drugs in this class
  3. Vaxine Pty Ltd · 2 drugs in this class
  4. D'Or Institute for Research and Education · 2 drugs in this class
  5. Protein Sciences Corporation · 2 drugs in this class
  6. Henogen · 1 drug in this class
  7. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
  8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
  9. National Vaccine and Serum Institute, China · 1 drug in this class
  10. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RSV-F Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/rsv-f-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: